Illumina - ILMN Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings or view top-rated stocks.

13 analysts have issued 12-month price targets for Illumina's shares. Their ILMN share price forecasts range from $175.00 to $492.00. On average, they anticipate the company's share price to reach $265.60 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price.
View analysts price targets for ILMN or view top-rated stocks among Wall Street analysts.

Illumina's stock was trading at $380.44 at the beginning of the year. Since then, ILMN shares have decreased by 49.3% and is now trading at $192.96.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ILMN earnings forecast.

Illumina, Inc. (NASDAQ:ILMN) announced its earnings results on Thursday, August, 11th. The life sciences company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.63 by $0.06. The life sciences company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.22 billion. Illumina had a negative net margin of 0.43% and a positive trailing twelve-month return on equity of 5.61%. Illumina's revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.87 earnings per share.
Read the conference call transcript.

Illumina updated its FY 2022 earnings guidance on Thursday, September, 8th. The company provided EPS guidance of $2.75-$2.90 for the period, compared to the consensus estimate of $4.12. The company issued revenue guidance of $4.71 billion-$4.75 billion, compared to the consensus revenue estimate of $5.19 billion.

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ILMN stock can currently be purchased for approximately $192.96.

Illumina (NASDAQ:ILMN) has a market capitalization of $30.31 billion and generates $4.53 billion in revenue each year. The life sciences company earns $762 million in net income (profit) each year or ($0.06) on an earnings per share basis.

The company employs 9,150 workers across the globe.

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for the company is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.